Fasenra is the second biologic approved for the condition. The decision follows a positive opinion from the Committee for ...

The new treatment will be a competitor of GSK’s Nucala (mepolizumab), which was approved in 2018 as the first targeted ...

AstraZeneca’s Fasenra (benralizumab) has been approved in the European Union (EU) as an add-on treatment for adult patients ...

AstraZeneca’s Fasenra (benralizumab) injected drug cuts the size of nasal polyps and nasal blockage in patients with chronic rhinosinusitis with nasal polyps (CRSwNP). The company announced top ...

The European Commission has approved the Committee for Medicinal Products for Human Use (CHMP) recommendation to change the terms of marketing authorization for Fasenra (benralizumab). It can now ...

The drug tested is known as benralizumab (SHAMAL). The multinational study, published on 7 December, was led by scientists ...

Patients with asthma who switched biologics multiple times were younger, more likely to identify as Black, and had more ...

AstraZeneca’s Fasenra (benralizumab) has been approved in the European Union (EU) as an add-on treatment for adult patients with relapsing or refractory eosinophilic granulomatosis with polyangiitis ...

Nov. 8, 2024 — Researchers identify a key pathway leading to neurodegeneration in early stages of ALS, hinting at the potential for short-circuiting the progression of the fatal disease if ...

November 4, 2024 • How did life start on Earth? The answer is a big scientific mystery scientists are actively investigating. After talking with many scientists, host Regina G. Barber found that ...

New indication supported by the MANDARA trial, which showed nearly 60% of patients achieved remission and 41% of patients fully stopped taking oral corticosteroidsAstraZeneca’s Fasenra (benralizumab) ...

Cambridge: AstraZeneca has announced that Fasenra (benralizumab) has been approved in the European Union (EU) as an add-on treatment for adult patients with relapsing or refractory ...